Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 191,300 shares, a decline of 44.8% from the March 31st total of 346,800 shares. Based on an average daily volume of 59,500 shares, the days-to-cover ratio is presently 3.2 days. Approximately 1.2% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Immix Biopharma in a research note on Monday, February 10th.

Institutional Investors Weigh In On Immix Biopharma

A number of hedge funds have recently made changes to their positions in the stock. SBI Securities Co. Ltd. bought a new stake in Immix Biopharma during the 4th quarter worth $38,000. Jane Street Group LLC bought a new stake in shares of Immix Biopharma in the fourth quarter worth $39,000. FNY Investment Advisers LLC acquired a new position in Immix Biopharma during the 4th quarter worth about $63,000. Finally, Geode Capital Management LLC raised its position in shares of Immix Biopharma by 5.6% during the third quarter. Geode Capital Management LLC now owns 150,082 shares of the company's stock worth $224,000 after acquiring an additional 7,954 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Price Performance

NASDAQ:IMMX traded up $0.06 during mid-day trading on Friday, reaching $2.10. The stock had a trading volume of 59,636 shares, compared to its average volume of 125,481. Immix Biopharma has a 12 month low of $1.26 and a 12 month high of $2.71. The stock has a market capitalization of $58.22 million, a PE ratio of -2.47 and a beta of 0.30. The stock has a 50-day simple moving average of $1.70 and a two-hundred day simple moving average of $1.87.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. Equities analysts expect that Immix Biopharma will post -0.87 EPS for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.